Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive subtype of kidney cancer, comprising 75 to 85% of all RCC cases. Over the past two decades, global incidence has doubled and mortality has risen by approximately 1% per year. When caught early, surgical intervention can achieve a 5-year survival rate of up to 93%, but nearly 40% of patients are diagnosed at advanced stages, where the 5-year survival drops below 20%.
Biomarkers are measurable indicators in blood, urine, or tissue that signal biological or pathological processes. For ccRCC, they serve three critical roles: enabling early diagnosis before symptoms appear, stratifying patients by risk of recurrence or progression, and predicting which patients will respond to specific targeted or immunotherapy drugs. Currently, no validated noninvasive biomarker test exists for ccRCC.
ccRCC frequently develops drug resistance to standard agents including tyrosine kinase inhibitors and immune checkpoint inhibitors. Identifying predictive biomarkers that anticipate resistance or sensitivity before treatment begins is essential for personalized therapy planning and for avoiding ineffective treatments that burden patients with toxicity without benefit.
Four molecular subgroups of ccRCC (ccRCC1 through ccRCC4) have been identified through transcriptome analysis. Patients with ccRCC2 and ccRCC3 tumors show significantly improved median overall survival and progression-free survival compared to ccRCC1 and ccRCC4 tumors. These molecular subtypes were the only significant covariates in multivariate Cox regression models for survival, underscoring their value as predictive markers for sunitinib treatment response.
PD-L1, the ligand for the PD-1 immune checkpoint, is expressed in 10 to 25% of ccRCC tumors and is associated with worse prognosis. Soluble forms of PD-L1 and PD-1 have been identified as independent prognostic factors for progression-free survival in sunitinib-treated patients. The co-expression of PD-L1 with AXL or HHLA2 further worsens prognosis, suggesting these combinations define a particularly aggressive tumor phenotype.
TLR3 (toll-like receptor 3), an innate immune sensor, is abundantly expressed in ccRCC tumors. In a sub-analysis of the AXIS trial comparing axitinib and sorafenib, high TLR3 expression was associated with longer progression-free survival in axitinib-treated patients, while low TLR3 expression predicted better outcomes on sorafenib, highlighting TLR3 as a potential biomarker for treatment selection between these two agents.
Inflammatory markers including C-reactive protein (CRP) and the neutrophil-to-lymphocyte ratio (NLR) are independent prognostic factors for poor survival in ccRCC. Elevated baseline CRP is associated with larger tumor size, higher grade and stage, lymphatic involvement, and aggressive histological features such as sarcomatoid morphology. Adding CRP to established prognostic models like IMDC improves their predictive accuracy for overall and progression-free survival on nivolumab.
DNA methylation patterns represent a powerful diagnostic and prognostic tool. A panel of 11 CpG sites distinguishes kidney cancer from normal tissue with approximately 90% sensitivity and 80% specificity in TCGA validation data. Urine-based methylation panels involving ZNF677 and PCDH8 achieve 69 to 78% sensitivity and 69 to 80% specificity for ccRCC detection, opening the door to non-invasive kidney cancer screening.
Carbonic anhydrase IX (CAIX) is upregulated by hypoxia-inducible factor 1-alpha and serves as both a diagnostic histological marker and a prognostic indicator. Elevated serum CAIX levels correlate with shortened overall survival in ccRCC patients (HR 2.65; p equals 0.014). CAIX is also being explored as a molecular imaging target, with agents such as 64Cu XYIMSR-06 enabling PET visualization of ccRCC tumors.
Exosomes are tiny extracellular vesicles secreted at 10 times the rate by cancer cells compared to normal cells. They carry disease-specific DNA, RNA, metabolites, and cell-surface proteins into the bloodstream. Exosomal microRNAs from ccRCC patients, including miR-30c-5p and combinations of miR-126-3p with miR-449a or miR-34b-5p, have shown diagnostic promise with AUC values reaching 0.84.
Cancer stem cell exosomes carrying miR-19b-3p promote metastasis by inhibiting PTEN expression in target cancer cells. CD103-positive exosomes selectively target cancer cells and organs, conferring enhanced lung metastatic capacity and serving as diagnostic markers for metastatic potential. These findings suggest that exosomal cargo profiling may reveal tumor behavior beyond what primary tumor biopsy can show.
Circulating tumor cells (CTCs) can be isolated using sensitive microfluidic platforms that detect renal-specific markers including cytokeratin, EpCAM, CAIX, and CAXII. CTC heterogeneity in ccRCC means that specific subsets rather than total CTC counts provide the most prognostically relevant information, with CK-positive CTC counts above 2.6 per milliliter correlating with radiographic progression.
Chromosome 3p deletions and mutations in tumor suppressor genes including VHL, PBRM1, BAP1, and SETD2 are present in over 90% of sporadic ccRCC cases. The VHL gene is the most commonly mutated, and its inactivation leads to accumulation of hypoxia-inducible factor (HIF) and downstream upregulation of angiogenic pathways. Fluorescence in situ hybridization targeting chromosome 3p alterations serves as a diagnostic tool for renal mass assessment.
MicroRNAs (miRNAs) are small non-coding RNAs detectable in serum, plasma, and urine. Several miRNA panels have been validated as diagnostic or prognostic markers in ccRCC. Downregulation of tumor suppressor miRNAs and overexpression of oncogenic miRNAs correlate with advanced stage, metastasis, and poor survival. Their stability in body fluids makes them attractive candidates for liquid biopsy-based screening.
BIRC5/Survivin, an inhibitor of apoptosis protein, serves as an independent predictor of ccRCC progression and mortality. Its co-expression with the anti-apoptotic receptor B7-H1 enhances predictive accuracy for tumor aggressiveness. Analysis of 1,994 ccRCC specimens found that high Survivin and positive B7-H1 expression together identify patients at elevated risk of disease-specific mortality.
The integration of artificial intelligence with multi-omics data including genomics, transcriptomics, proteomics, and radiomics holds promise for building more accurate and clinically actionable biomarker panels. Computational models trained on large multi-institutional datasets can identify combinations of markers that no individual marker achieves alone, improving both diagnostic sensitivity and prognostic specificity.
Radiogenomics, which links imaging features with molecular profiles, represents a frontier in non-invasive ccRCC characterization. CT or MRI imaging phenotypes correlated with underlying genetic alterations could enable molecular subtyping without biopsy, directly informing treatment selection. Similarly, biomaterial-based immunomodulation combined with biomarker-driven patient selection may optimize immunotherapy outcomes.
Despite the breadth of candidate biomarkers reviewed, clinical translation remains limited by the lack of prospective validation studies, standardized assay protocols, and regulatory approval. Future research must prioritize head-to-head comparison of biomarker panels in well-powered randomized trials to establish clinically actionable thresholds that can be reliably applied across institutions.